← Leaderboards
Veronique Dartois
University Of Minnesota
$28,450,941
Attributed
$43,562,412
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,562,412 · 20
By mechanism
U19$19,235,313 · 10
R01$17,704,101 · 5
U01$2,949,071 · 1
P01$2,729,900 · 2
S10$944,027 · 2
Top collaborators
- David Alland13 shared
- Padmini Salgame8 shared
- Michael Stephen Glickman7 shared
- Denise E Kirschner6 shared
- Courtney C Aldrich5 shared
- Dirk Schnappinger5 shared
- Thomas Dick4 shared
- Joanne L. Flynn4 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Courtney C Aldrich$9,602,262
- Dirk Schnappinger$17,202,306
- Christy Hagan$1,691,746
- Diana J. Wallin$72,150
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsProgramsDrug KineticsMycobacterium TuberculosisInfectionTuberculosisBaseIn VivoOryctolagus CuniculusTuberculosis DrugsPathogenIn VitroRegimenPharmacodynamicsBacteriaLesionMutantSitePharmacologyPenetrationDoseGeneticCellsTissues
Grant awards (64)
Pharmacology & ImmunoPathology (PIP) Core$597,325
U19 · FY2025 · AI · contact PI
Core B: Animal Model Core$494,578
P01 · FY2025 · AI · contact PI
Core B: Animal Model Core$494,578
P01 · FY2024 · AI · contact PI
Pharmacology & ImmunoPathology (PIP) Core$494,051
U19 · FY2024 · AI · contact PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis$779,863
R01 · FY2023 · AI
Core B: Animal Model Core$756,923
P01 · FY2023 · AI · contact PI
Pharmacology & ImmunoPathology (PIP) Core$529,260
U19 · FY2023 · AI · contact PI
Pharmacology Core$3,475,988
U19 · FY2022 · AI · contact PI
Core C Pharmacology$864,677
U19 · FY2022 · AI · contact PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis$779,863
R01 · FY2022 · AI
Pharmacology & ImmunoPathology (PIP) Core$472,717
U19 · FY2022 · AI · contact PI
Core B: Animal Model Core$468,908
P01 · FY2022 · AI · contact PI
Lesion-centric optimization of multidrug therapies for tuberculosis$832,259
R01 · FY2021 · AI
Target based discovery of next generation pyrazinamide$794,409
R01 · FY2021 · AI · contact PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis$779,863
R01 · FY2021 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$736,322
R01 · FY2021 · AI · contact PI
Core C Pharmacology$606,472
U19 · FY2021 · AI · contact PI
Pharmacology & ImmunoPathology (PIP) Core$550,701
U19 · FY2021 · AI · contact PI
Core B: Animal Model Core$514,913
P01 · FY2021 · AI · contact PI
Lesion-centric optimization of multidrug therapies for tuberculosis$869,259
R01 · FY2020 · AI
Target based discovery of next generation pyrazinamide$797,081
R01 · FY2020 · AI · contact PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis$779,863
R01 · FY2020 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$770,673
U19 · FY2020 · AI · contact PI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$750,865
R01 · FY2020 · AI · contact PI
Core C Pharmacology$616,666
U19 · FY2020 · AI · contact PI
Pharmacology$601,886
U19 · FY2020 · AI · contact PI
Target based discovery of next generation pyrazinamide$838,267
R01 · FY2019 · AI · contact PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis$820,039
R01 · FY2019 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$777,574
U19 · FY2019 · AI · contact PI
A Multi-scale systems pharmacology approach to TB therapy$717,296
U01 · FY2019 · HL
Core C Pharmacology$594,171
U19 · FY2019 · AI · contact PI
Pharmacology$501,029
U19 · FY2019 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$786,135
R01 · FY2018 · AI
Target based discovery of next generation pyrazinamide$769,649
R01 · FY2018 · AI · contact PI
A Multi-scale systems pharmacology approach to TB therapy$717,122
U01 · FY2018 · HL
Pharmacology$485,623
U19 · FY2018 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$385,878
U19 · FY2018 · AI · contact PI
In Vitro and In Vivo Pharmacokinetics Core$330,828
U19 · FY2018 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$264,427
U19 · FY2018 · AI · contact PI
In Vitro and In Vivo Pharmacokinetics Core$253,775
U19 · FY2018 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$788,371
R01 · FY2017 · AI · contact PI
A Multi-scale systems pharmacology approach to TB therapy$714,113
U01 · FY2017 · HL
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$587,529
U19 · FY2017 · AI · contact PI
A QTRAP 6500 LC-MS/MS System from SCIEX for high accuracy drug content analysis$526,083
S10 · FY2017 · OD · contact PI
In Vitro and In Vivo Pharmacokinetics Core$520,992
U19 · FY2017 · AI · contact PI
Pharmacology$491,841
U19 · FY2017 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$1,072,858
R01 · FY2016 · AI · contact PI
A Multi-scale systems pharmacology approach to TB therapy$800,540
U01 · FY2016 · HL
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection$788,180
R01 · FY2016 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$543,503
U19 · FY2016 · AI · contact PI
In Vitro and In Vivo Pharmacokinetics Core$487,591
U19 · FY2016 · AI · contact PI
Pharmacology$407,224
U19 · FY2016 · AI · contact PI
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection$788,890
R01 · FY2015 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$788,126
R01 · FY2015 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$606,449
U19 · FY2015 · AI · contact PI
Pharmacology$482,557
U19 · FY2015 · AI · contact PI
In Vitro and In Vivo Pharmacokinetics Core$465,845
U19 · FY2015 · AI · contact PI
A MALDI LTQ Orbitrap XL Mass Spectrometer for BioImaging$417,944
S10 · FY2015 · OD · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$802,715
R01 · FY2014 · AI · contact PI
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection$789,586
R01 · FY2014 · AI · contact PI
Pharmacology$624,658
U19 · FY2014 · AI · contact PI
In Vitro and In Vivo Pharmacokinetics Core$460,655
U19 · FY2014 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$382,748
U19 · FY2014 · AI · contact PI
Lesion-centric imaging and PK-PD of pyrazinamide for TB/HIV co-infection$771,638
R01 · FY2013 · AI · contact PI